Dianhydrodulcitol (BioDeep_00000842070)

   


代谢物信息卡片


Dianhydrodulcitol

化学式: C6H10O4 (146.057906)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1C(O1)C(C(C2CO2)O)O
InChI: InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2

描述信息

D009676 - Noxae > D000477 - Alkylating Agents
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

Dianhydrodulcitol



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Lihan Sun, Huajing Wu, Lianjie Ren, Jiaojiao Cong, Xiaohui Qin, Xingli Wang, Xinming Qi, Lifeng Kang, Junying Zhang, Chunyong Wu. Development and validation of a highly sensitive LC-MS/MS method for determination of brain active agent dianhydrogalactitol in mouse plasma and tissues: Application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Jun; 1087-1088(?):90-97. doi: 10.1016/j.jchromb.2018.04.026. [PMID: 29730531]
  • P Anderlik, K Antmann, Z Bános. [Effect of immunosuppressive agents and antilymphocyte serum on bacterial translocation in mice]. Acta pharmaceutica Hungarica. 1999 Apr; 69(2):69-71. doi: NULL. [PMID: 10389300]
  • P Anderlik, K Antmann, Z Bános. Effect of antilymphocyte serum on bacterial translocation in mice. Acta microbiologica et immunologica Hungarica. 1998; 45(2):257-61. doi: NULL. [PMID: 9768294]
  • S L Kelley, W P Peters, J Andersen, E A Furlong, E Frei, W D Henner. Pharmacokinetics of dibromodulcitol in humans: a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 May; 4(5):753-61. doi: 10.1200/jco.1986.4.5.753. [PMID: 3517245]
  • I P Horváth, J Csetényi, S Kerpel-Fronius, L Hegedüs, B Kanyár, S Eckhardt. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD. European journal of cancer & clinical oncology. 1986 Feb; 22(2):163-71. doi: 10.1016/0277-5379(86)90026-x. [PMID: 3699079]
  • S Kerpel-Fronius, V Erdélyi-Tóth, F Gyergyay, I Hindy, Z Mechl, M Nekulová, S Somfai-Relle, P Kovács, G Ujj, B Kanyár. Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG). Cancer chemotherapy and pharmacology. 1986; 16(3):264-8. doi: 10.1007/bf00293989. [PMID: 3698168]
  • V Erdélyi-Tóth, S Kerpel-Fronius, B Kanyár, S Eckhardt. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG). Cancer chemotherapy and pharmacology. 1986; 16(3):257-63. doi: 10.1007/bf00293988. [PMID: 3698167]
  • Dam Viet Cuong, G Kulcsár, R Vámos, P Dán, I Nász. Interaction of immunosuppressive agents and human adenovirus infection in mice. Acta microbiologica Hungarica. 1986; 33(1):33-8. doi: NULL. [PMID: 3019068]
  • V Ratanatharathorn, L H Baker, L Balducci, R W Talley, B Hoogstraten. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study. Cancer treatment reports. 1982 May; 66(5):1231-2. doi: NULL. [PMID: 7083224]
  • R T Eagan, M M Ames, G Powis, J S Kovach. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. Cancer treatment reports. 1982 Feb; 66(2):283-7. doi: NULL. [PMID: 7034934]
  • K Tóth, J Sugár, S Somfai-Relle, L Hedegüs. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay. Carcinogenesis. 1982; 3(3):333-6. doi: 10.1093/carcin/3.3.333. [PMID: 7044598]
  • P Kubisz, F Seghier, P Klener, S Cronberg. Influence of dianhydrogalactitol on some platelet functions in vitro. Acta haematologica. 1981; 66(1):27-30. doi: 10.1159/000207087. [PMID: 6794295]
  • C D Haas, L Baker, T Thigpen. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study. Cancer treatment reports. 1981 Jan; 65(1-2):115-7. doi: NULL. [PMID: 6261943]
  • R G Hahn, M Bauer, J Wolter, R Creech, J M Bennett, G Wampler. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer treatment reports. 1979 Mar; 63(3):513-5. doi: NULL. [PMID: 371804]